Caira Surgical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Caira Surgical is an innovative, pre-revenue medical device startup focused on revolutionizing joint replacement surgery through its proprietary radar-based navigation technology. The company, founded in 2015 by a surgeon dissatisfied with existing options, aims to deliver sub-millimeter precision with a system that is more intuitive, efficient, and affordable than current robotic and optical navigation platforms. With a veteran team and key patents secured, Caira is developing its first product for knee arthroplasty, targeting a significant reduction in setup time and equipment cost to improve global access to precision surgery.

OrthopedicsSurgery

Technology Platform

Proprietary radar-based surgical tracking technology and integrated software platform designed for computer-aided navigation in joint replacement surgery, aiming to eliminate line-of-sight issues and reduce cost/complexity.

Opportunities

Caira has the opportunity to democratize precision joint replacement by offering a high-precision navigation system at a significantly lower cost than current robotic platforms, potentially capturing market share in ambulatory surgery centers and community hospitals globally.

Its radar-based technology also offers a tangible clinical differentiation by eliminating line-of-sight obstructions, a common frustration with existing optical navigation systems.

Risk Factors

Key risks include the unproven clinical performance of its novel radar tracking system, significant regulatory hurdles to achieve market clearance, and the formidable challenge of commercializing a new platform against deeply entrenched competitors with vast sales and training resources.

As a pre-revenue company, it also faces financial risk dependent on continued investor funding.

Competitive Landscape

Caira competes in the crowded and fast-growing market for orthopedic surgical navigation and robotics, dominated by large medtech players like Stryker (Mako), Zimmer Biomet (ROSA), Johnson & Johnson (VELYS), and Smith & Nephew (Cori). Its primary competitive angles are potential cost (10x improvement claimed), workflow simplicity (5x faster setup), and the technical advantage of radar over optical tracking.

More companies in Digital Health & Biotech SaaS →More companies in United States →